BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax, a BCL-2 inhibitor, is the only inhibitor of this family of anti–apoptotic proteins approved for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and acute myeloid leukemia [2].